Member Info for one4one

Diggitt the self confessed crank :-)) this is not a case off rolling up your shirt sleeve and having a infusion Aml is a difficult disease many have failed 🐭

Made transfer you do not know if it works as they are Testing, if thunderbirds has lift off to full dosage will toxicity creep in ! the trial is in the early stage of ensuring safety as a priority to efficacy ,negative data will collapse the foundations of the share price, also in the shadows is further equity raises to fund the clinical trial to progress.... so the route to commercialising is not on the sat-nav yet🐭

Lock in your losses with a bed & isa lol:-))) then wait for financle first aid of the warrants being exercised of which will accumulate the shares already in issue

Defibrillator on standbye 🐭

the manufacturing transfer was welcomed as this levitates hemogenyx cash burn, as you are aware ,hemo genyx is autologous of which is a custom therapy per cohort.... when vlad was in the ****pit the manufacturing was 4 weeks, "made tech " can slim this down with the adaption of ai/robotic assistance. the first 3 cohorts received a half dose of hg-ct-1 with no toxicity this enabled the c/t to progress so now the first 3 cohorts are being primed to receive a top up to a full dose under the "made tech" so therefore a slight delay and fresh data will provide efficacy so the next move will come from patient outcome (remission data) not clinical trial progress before the next cohorts are enrolled to join the clinical trial🐭

Bed &isa T3/trade "3 working days" to execute pending volume/looking at the trades i see little movement of duplicate trades as they are usually marked with a -minus symbol followed by a * star symbol why the rush as you have 12 months to get your house keeping in order & whilst invested it is not taxable

if and when your investment hits the isa threshold eclipse the transfer on the eve of the last day of this years isa allowance and the start of the new financle year my self being a honest citizen of the uk buys Britannia gold as it is exempt from vat🐭

Breaking news....Artemis11 has located vast volumes of helium on the moon, this out of this world exploration will be a relief for a parched planet earth as the helium reserves dehydrate:-))

Where are we, what has actually been achieved: Hemogenyx Pharmaceuticals plc has raised £2,500,000 through a direct subscription of 333,333 new ordinary shares at £7.50 per share, with new investors also receiving warrants. These funds will primarily support the continuation of Phase I clinical trials for HG-CT-1, further hemogenyx have outsourced the manufacturing The company has also reduced its burn rate by outsourcing HG-CT-1 manufacturing. Following admission, the enlarged issued share capital will comprise 6,374,588 ordinary shares.

three of 18 adult patients treated, All passed initial safety checks, No dose-limiting toxicity so far the Trial progressed to higher dose cohort, Early encouraging efficacy signals NOT confirmed yet, the Paediatric trial arm opened, this is why the stock ran hard  trial continuation &.safety success that's why you witnessed a 10x movement because the market priced in hemogenyx achievement. Market reaction spike...fade this signals to traders. De-risking” (safety looks good) “Progression” (moving up doses) Optionality” (paediatric + expansion) BUT No confirmed remission data yet....No hard efficacy proof, sell into strength ! so the sp is choppy & remains in No-mans-land for how long ? that depends on on-coming data!

If you brought @ a higher price than present you are not investing you are Gambling🐭

@Toukankahmoon you are on course: timing is the essence before the c/t hemogenyx was on the market for financle support "traders paradise" the mint fiasco was a blessing:-)) but to cut the chase the c/t is evolving but caution the sp will still have pitfalls may i remind the bulls the c/t is in the early stages and the cash burn is smouldering so further dilution is on the cards if you play your cards rite buy the dips sell into the news "game of thrones" as the c/t evolves study the wording of the rns Efficacy will open pandora box🐭

Expected - Windows

April → Patient selection

May → Manufacturing + scalability/release

June → DL2 dosing

July → Safety readout

August → Early efficacy

September → Cohort completion + corporate action

3. Market Impact (Typical Ranges)

Recruitment → +10–20%

Manufacturing → +10–25%

DL2 dosing → +20–40%

Clean safety → +20–50%

Efficacy → +50–150%

Corporate action → +30–200

Bottom line

Clean safety data + repeat positive responses → bullish outcome for the share price

Mixed or unclear efficacy → the stock may stagnate

Signs of toxicity → the share price could fall significantly (potentially ~50%)

critical control points

Consistent responses across multiple patients (not just one)

Potential toxicity at higher doses

scalability yes or no ?

Hemogenyx has reached an important anchor point. Three patients have received infusions at a half dose, and the DSMB has approved dose escalation along with pediatric expansion. With the safety de-risking phase completed, Hemogenyx is now moving into the efficacy phase, where infection response will be evaluated......the recent RNS re-assures market confidence but will remain sensitive to news flow.

What to expect next (3–6 months):

During Phase 1, dose escalation of HG-CT-1 will continue across multiple patients. With the safety window now completed, the company is entering the key efficacy phase — a potential inflection point where the stock could either trend upward or back-flip, gentlemen please take a seat at the table " The game is about to start " Place your bets & enjoy the game🐭

Mr Jinx did you miss me:-)) My post was collated from my research🍒 have a lovely easter break !

“If you are holding, you may remain in regression — fear is the tax on indecision.🐭

Https://hemogenyx.com/technology/

FLT3‑positive AML is one of the fastest‑moving and deadliest blood cancers. That’s why combining CDX and HG‑CT‑1 isn’t just clever — it’s necessary !

HG-CT-1 & CDX integrated pathway cdx speed accessibility /conditioning / maintenance HG-CT-1 durability curative potential a unique dual platform that places hemogenyx in a position ahead of other prospectors most companies own one part of the pathway Hemogenyx is in a position to own Both of them to eradicate FL3 + AML

this dual pathway eclipses two streams of revenue thus gives hemogenyx a unique clinical protocol big farmer loves platforms that span multiple acres of care:-)) create multi-billion $ value & HG-CT-1 + CDX IS Exactly That

car-t is limited by patient fitness & manufacturing time cdx is immediate accessible useable in older frail patients compatible with transplant conditioning cdx can reach more patients than car-t alone cdx implements access to global markets generating revenue while car-t grows

cdx & hg-ct-1 working in tandem stabilizing Flt3-Aml preventing disease progression

this solves a weakness of autologous car-t in "AML" as the patients cannot wait 3-4 weeks manufacturing if the disease is progressing .CDX fills the void.& prevents relapse,

companies like BMS...AMGEN,,,REGENERON,,,ROACH,& NOVARTIS have all explored the bi-specifics for AML but none have a molecule with CDX combination "CDX" fills a gap the industry has being trying to solve.so to to recap...off the shelf...safer t-cell activation. .replace Toxic chemotherapy, in combination with HG-CT-1 Hemogenyx would have control of both ,The curative car-t therapy & the conditioning agent CDX a rare & commercially powerful prospect.

No other company has both modalities for FLT3. This dual‑platform approach could redefine AML treatment by combining immediate stabilisation with long‑term disease eradication.

In short: CDX buys time. HG‑CT‑1 buys survival. Together, they offer something AML has never had — a complete immunotherapy pathway.🐭

Refreshing to to read the forum on the science ,great utube vid Abh, now the tech transfer is sealed the science can move on in the direction of MDA selecting the next cohorts to be enrolled if they haven`t all ready done so ! 🐭

• Strategy: accumulate early, add on confirmation, trim into strength.

• Catalysts (Apr–Sep): recruitment → manufacturing → dosing → safety → efficacy → corporate action.

• Expected Moves: +10–20%, +10–25%, +20–40%, +20–50%, +50–150%, +30–200%.

• Strategy: accumulate early, add on confirmation, trim into strength.

Lostapound keep ploughing the field of dreams country miles lay ahead🐭

Hemogenyx starting their first‑in‑human CAR‑T trial with a half‑dose is completely standard for early cell‑therapy development. It’s not a sign of weakness or delay — it’s a regulator‑approved safety step used across the entire CAR‑T industry. The FDA doesn’t force a 28‑day wait before escalation; the company simply follows the safety window in its IND, and most CAR‑T toxicities show up within 7–14 days. Once that window is clear, they can move to the full dose without unnecessary downtime. This is the same disciplined, stepwise approach every successful CAR‑T therapy has taken. For investors, it shows Hemogenyx is managing risk properly, generating clean data, and progressing the program in a controlled, value‑protective way🐭

Quote of the day.

Long road ahead yet and p1 DE trial is all about finding the optimum dose to then take in p2. View it through that lens and you won't be disappointed.

In a nutshell hemogenyx is generating clean safety data/progressing the c/t in a controlled predictable manner and managing risk🐭

Hemogenyx starting their first‑in‑human CAR‑T trial with a half‑dose is completely standard for early cell‑therapy development. It’s not a sign of weakness or delay — it’s a regulator‑approved safety step used across the entire CAR‑T industry. The FDA doesn’t force a 28‑day wait before escalation; the company simply follows the safety window in its IND, and most CAR‑T toxicities show up within 7–14 days. Once that window is clear, they can move to the full dose without unnecessary downtime. This is the same disciplined, stepwise approach every successful CAR‑T therapy has taken. For investors, it shows Hemogenyx is managing risk properly, generating clean data, and progressing the program in a controlled, value‑protective way🐭

Micky it is well known that the cells split and multiply therefore this overloads the system/ think about i know its hard/why did vlad not administrate the full dose at the start ?....🐭

Autologous is a custom 121 therapy some claim scalable if so there may be a issue with the patent & patients copy rites....royalty payments per infusion🐭

Mickyc333 please do not look at the Picture.....Look into the picture and you will see a fresh landscape🐭